Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Issue 18 (20th April 2022)

• Record Type: Journal Article
• Authors: Zerbo, Ousseny; Modaressi, Sharareh; Goddard, Kristin; Lewis, Edwin; Fireman, Bruce; Daley, Matthew F.; Irving, Stephanie A.; Jackson, Lisa A.; Donahue, James G.; Qian, Lei; Getahun, Darios; DeStefano, Frank; McNeil, Michael M.; Klein, Nicola P.
• Is Part Of: Vaccine. Volume 40:Issue 18(2022)
• Page Start: 2568
• Page End: 2573
• Publication Date: 2022-04-20
• Subjects: Vaccine -- Autism -- Fever -- Febrile seizures pertussis-containing vaccine -- MMR/MMRV; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.03.031
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Fever and ED risks after measles- or pertussis-containing vaccines are similar in children with and without ASD. No significant increased risk of fever or ED visits after measles- or pertussis-containing vaccines among children with ASD. Measles- or pertussis-containing vaccines are safe for both children with and without ASD. Abstract: Objectives: To determine whether children aged 4–7 years with a diagnosis of autism spectrum disorders (ASD) were at increased risk of fever, febrile seizures, or emergency department (ED) visits following measles- or pertussis-containing vaccines compared with children without ASD. Methods: The study included children born between 1995–2012, aged 4–7 years at vaccination, and members of six healthcare delivery systems within Vaccine Safety Datalink. We conducted self-controlled risk interval analyses comparing rates of outcomes in risk and control intervals within each group defined by ASD status, and then compared outcome rates between children with and without ASD, in risk and control intervals, by estimating difference-in-differences using logistic regressions. Results: The study included 14, 947 children with ASD and 1, 650, 041 children without ASD. After measles- or pertussis-containing vaccination, there were no differences in association between children with and without ASD for fever (ratio of rate ratio for measles-containing vaccine = 1.07, 95% CI 0.58–1.96; for pertussis-containing vaccine = 1.16, 95% CI 0.63–2.15) or ED visits (ratio of rate ratio for measles-containing vaccine = 1.11, 95% CI 0.80–1.54; for pertussis-containing vaccine = 0.87, 95% CI 0.59–1.28). Febrile seizures were rare. Pertussis-containing vaccines were associated with small increased risk of febrile seizures in children without ASD. Conclusion: Children with ASD were not at increased risk for fever or ED visits compared with children without ASD following measles- or pertussis-containing vaccines. These results may provide further reassurance that these vaccines are safe for all children, including those with ASD.